Are targeted prostate biopsies ready to replace systematic prostate biopsies?

Las biopsias de próstata dirigidas ¿están listas para reemplazar las biopsias de próstata sistemáticas?

Journal

Actas urologicas espanolas
ISSN: 2173-5786
Titre abrégé: Actas Urol Esp (Engl Ed)
Pays: Spain
ID NLM: 101771154

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 29 12 2017
revised: 07 06 2018
accepted: 09 06 2018
pubmed: 5 11 2019
medline: 3 10 2020
entrez: 5 11 2019
Statut: ppublish

Résumé

To evaluate the efficacy and efficiency of systematic prostatic biopsy (SPB) and cognitive fusion PB (CFPB) to diagnose prostate cancer (PCa) and significant PCa (SPCa), and to analyse if CFPB could safely replace SPB. A cohort of 314 consecutive men having PI-RADS ≥2 in a pre-biopsy 3T mp-MRI were prospectively subjected to trans-rectal ultrasound CFPB (two cores per suspicious area until a maximum of three areas) and a 12 peripheral core SPB. SPCa was considered when the WHO grade was higher than 2 (Gleason 4+3 or higher). PCa was diagnosed in 133 patients (42.4%), being 83 (62.4%) SPCa. SPB detected PCa in 114 men (85.7%) while CFPB in 103 (77.4%), P<.001. SPB detected SPCa in 64 men (77.1%) while CFPB in 71 (85.5%), P<.001. In 52 of the 81 men (64.2%) SPCa was detected in SPB and CFPB. In 19 men SPCa was only detected in CFPB (23.5%) while in 10, it was only detected in SPB (12.3%). 33.1 cores were needed to diagnose one PCa in SPB while 8.5 in CFPB, P<.001. 58.9 cores were needed to diagnose one SPCa in SPB, while 12.4 in CFPB, P<.001. CFPB are more effective and also more efficient than SPBs in detecting SPCa. However, CFPBs still can't safely replace SPBs because they are not able to detect up to 15% of SPCa.

Identifiants

pubmed: 31679807
pii: S0210-4806(19)30116-0
doi: 10.1016/j.acuro.2018.06.011
pii:
doi:

Substances chimiques

KLK3 protein, human EC 3.4.21.-
Kallikreins EC 3.4.21.-
Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Comparative Study Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

573-578

Informations de copyright

Copyright © 2019 AEU. Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

A Celma (A)

Departamento de Urología, Hospital Universitario Vall d'Hebron, Barcelona, España. Electronic address: acelma@vhebron.net.

R López (R)

Departamento de Urología, Hospital Universitario Vall d'Hebron, Barcelona, España.

S Roche (S)

Departamento de Urología, Hospital Universitario Vall d'Hebron, Barcelona, España.

J Planas (J)

Departamento de Urología, Hospital Universitario Vall d'Hebron, Barcelona, España.

L Regis (L)

Departamento de Urología, Hospital Universitario Vall d'Hebron, Barcelona, España.

J Placer (J)

Departamento de Urología, Hospital Universitario Vall d'Hebron, Barcelona, España.

A Borque (A)

Departamento de Urología, Hospital Miguel Servet, Zaragoza, España.

L M Esteban (LM)

EP de La Almunia, Universidad de Zaragoza, La Almunia de Doña Godina, Zaragoza, España.

I de Torres (I)

Departamento de Patología, Hospital Universitario Vall d'Hebron, Barcelona, España.

J Morote (J)

Departamento de Urología, Hospital Universitario Vall d'Hebron, Barcelona, España.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH